Clinical Approach to Amenorrhea
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of amenorrhea and infrequent periods
Amenorrhea and oligomenorrhea are among the most common gynecological complaints, affecting approximately 3-4% of reproductive-aged women. Secondary amenorrhea occurs in up to 5% of women at some point during their reproductive years. Primary amenorrhea, while less common (affecting 0.1-0.3% of adolescents), often signals significant underlying pathology requiring thorough evaluation. Beyond fertility concerns, menstrual irregularities serve as important indicators of broader metabolic, endocrine, and reproductive health, making systematic evaluation essential.
Definitions
Primary Amenorrhea: Absence of menarche by age 15 in the presence of normal secondary sexual characteristics, OR absence of menarche by age 13 without secondary sexual development.
Secondary Amenorrhea: Absence of menstruation for 3 or more consecutive months in a woman who previously had regular cycles, OR 6 months in a woman with previously irregular cycles.
Oligomenorrhea: Menstrual cycles occurring at intervals greater than 35 days, or fewer than 9 cycles per year.
Classification by Type
| Category | Definition | Common Causes | Clinical Significance |
|---|---|---|---|
| Primary Amenorrhea | No menarche by age 15 (with breast development) or age 13 (without breast development) | Gonadal dysgenesis (Turner syndrome), Müllerian agenesis, constitutional delay, hypothalamic-pituitary disorders | Often indicates chromosomal, anatomical, or significant endocrine abnormality; requires comprehensive workup |
| Secondary Amenorrhea | Absence of menses for ≥3 months (regular cycles) or ≥6 months (irregular cycles) | Pregnancy, hypothalamic amenorrhea, polycystic ovary syndrome, hyperprolactinemia, premature ovarian insufficiency | Most cases are functional; always exclude pregnancy first; may indicate systemic disease |
| Oligomenorrhea | Cycles >35 days apart or <9 cycles per year | Polycystic ovary syndrome (most common), thyroid dysfunction, hyperprolactinemia, perimenopause | Often precedes amenorrhea; associated with anovulation and infertility; increased endometrial cancer risk with prolonged anovulation |
Classification by Anatomical Compartment
The compartmental approach organizes causes of amenorrhea by the level of the hypothalamic-pituitary-ovarian-uterine axis affected. This framework directly guides diagnostic workup and treatment.
Compartment I: Uterus and Outflow Tract
Anatomical abnormalities preventing menstrual flow despite normal ovarian function. Includes Müllerian agenesis, imperforate hymen, transverse vaginal septum, and Asherman syndrome (intrauterine adhesions).
Compartment II: Ovary
Primary ovarian pathology causing inadequate estrogen production or follicular development. Includes gonadal dysgenesis (Turner syndrome), premature ovarian insufficiency, and polycystic ovary syndrome.
Compartment III: Anterior Pituitary
Pituitary disorders affecting gonadotropin secretion. Includes prolactinoma, other pituitary adenomas, Sheehan syndrome (postpartum pituitary necrosis), and empty sella syndrome.
Compartment IV: Hypothalamus and Central Nervous System
Disorders affecting gonadotropin-releasing hormone (GnRH) secretion. Includes functional hypothalamic amenorrhea (stress, weight loss, exercise), Kallmann syndrome, and hypothalamic tumors.
World Health Organization Classification
| WHO Group | Gonadotropins | Estrogen | Examples | Approximate Frequency |
|---|---|---|---|---|
| Group I | Low or normal | Low | Hypothalamic amenorrhea, Kallmann syndrome | 10-15% |
| Group II | Normal | Normal | Polycystic ovary syndrome, idiopathic anovulation | 70-85% |
| Group III | High | Low | Premature ovarian insufficiency, gonadal dysgenesis | 5-10% |
| Group IV | Variable | Variable | Outflow tract obstruction, Asherman syndrome | 5% |
| Group V | Normal (with elevated prolactin) | Variable | Hyperprolactinemia (tumor or drug-induced) | 15-20% |
The “Big Five” Causes of Secondary Amenorrhea: In clinical practice, five diagnoses account for approximately 90% of secondary amenorrhea cases:
- Pregnancy — always exclude first
- Polycystic ovary syndrome — most common pathological cause
- Hypothalamic amenorrhea — related to stress, weight loss, or excessive exercise
- Hyperprolactinemia — drug-induced or prolactinoma
- Premature ovarian insufficiency — ovarian failure before age 40
Key Epidemiology
- Polycystic ovary syndrome affects 6-12% of reproductive-aged women and is the leading cause of anovulatory infertility
- Functional hypothalamic amenorrhea accounts for 20-35% of secondary amenorrhea cases
- Premature ovarian insufficiency affects 1% of women under age 40 and 0.1% under age 30
- Hyperprolactinemia is found in 15-20% of women with amenorrhea
- Turner syndrome occurs in approximately 1 in 2,500 live female births and is the most common cause of primary amenorrhea with absent breast development
2. Pathophysiology and Mechanisms
Understanding the hypothalamic-pituitary-ovarian-uterine axis and mechanisms of menstrual dysfunction
Normal menstruation requires the coordinated function of four anatomical compartments: the hypothalamus, anterior pituitary, ovaries, and uterus with its outflow tract. The hypothalamic-pituitary-ovarian (HPO) axis operates through a sophisticated feedback system, with disruption at any level resulting in menstrual irregularity or amenorrhea. Understanding these mechanisms is essential for logical diagnostic workup and treatment selection.
The Hypothalamic-Pituitary-Ovarian Axis
| Component | Structure | Hormones/Function | Clinical Relevance |
|---|---|---|---|
| Hypothalamus | Arcuate nucleus, median eminence | Pulsatile GnRH secretion (every 60-120 minutes); coordinates reproductive axis | Sensitive to stress, weight, energy balance; disruption causes hypogonadotropic hypogonadism |
| Anterior Pituitary | Gonadotroph cells | Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion in response to GnRH | Suppressed by prolactin; damaged in Sheehan syndrome; site of pituitary adenomas |
| Ovary | Follicles, corpus luteum, stroma | Estrogen (follicular phase), progesterone (luteal phase); follicular development and ovulation | Depleted follicle pool causes premature ovarian insufficiency; abnormal folliculogenesis in polycystic ovary syndrome |
| Uterus | Endometrium, myometrium, cervix | Proliferation (estrogen), secretory transformation (progesterone), menstrual shedding (hormone withdrawal) | Requires intact outflow tract; scarring causes Asherman syndrome; absent in Müllerian agenesis |
Hormonal Feedback Mechanisms
Negative Feedback
Mediators: Estrogen, progesterone, inhibin B
Action: Suppresses GnRH pulsatility and gonadotropin release
Clinical relevance: Explains elevated FSH in ovarian failure (loss of negative feedback); basis of hormonal contraception
Positive Feedback
Mediator: Rising estradiol (>200 pg/mL for >50 hours)
Action: Triggers LH surge and ovulation
Clinical relevance: Absent in anovulatory cycles; basis of ovulation induction protocols
Kisspeptin System
Location: Hypothalamic arcuate and anteroventral periventricular nuclei
Action: Master regulator of GnRH neuron activity; integrates metabolic and reproductive signals
Clinical relevance: Links energy status to reproduction; explains hypothalamic amenorrhea in energy deficit
How Specific Conditions Cause Amenorrhea
| Condition | Mechanism | Hormonal Pattern | Treatment Implication |
|---|---|---|---|
| Functional Hypothalamic Amenorrhea | Suppressed GnRH pulsatility due to energy deficit, stress, or excessive exercise; mediated by reduced kisspeptin signaling and increased cortisol | Low FSH, low LH, low estradiol | Address underlying cause (nutrition, stress reduction); consider hormonal therapy for bone protection |
| Polycystic Ovary Syndrome | Increased GnRH pulse frequency favors LH over FSH; excess androgens and insulin resistance disrupt follicular development; follicles arrest at antral stage | Elevated LH:FSH ratio (often >2:1), elevated androgens, normal or low estradiol | Weight loss and lifestyle modification; metformin for insulin resistance; ovulation induction if fertility desired |
| Hyperprolactinemia | Elevated prolactin inhibits GnRH pulsatility; suppresses gonadotropin release; causes anovulation | Elevated prolactin, low-normal FSH and LH, variable estradiol | Dopamine agonists (cabergoline, bromocriptine) to lower prolactin; evaluate for pituitary adenoma |
| Premature Ovarian Insufficiency | Accelerated follicular atresia or initial reduced follicle pool; loss of negative feedback from ovarian hormones | Elevated FSH (>25-40 mIU/mL on two occasions), low estradiol, low anti-Müllerian hormone | Hormone replacement therapy until natural menopause age; donor oocytes for fertility |
| Thyroid Dysfunction | Hypothyroidism: elevated thyrotropin-releasing hormone (TRH) stimulates prolactin; altered sex hormone-binding globulin (SHBG) and peripheral estrogen metabolism | Abnormal thyroid-stimulating hormone (TSH), may have elevated prolactin | Thyroid hormone replacement normalizes menstrual function in most cases |
| Asherman Syndrome | Intrauterine adhesions (synechiae) from trauma to basalis layer, typically from dilation and curettage; prevents endometrial regeneration | Normal hormonal pattern (demonstrates intact HPO axis) | Hysteroscopic adhesiolysis; estrogen therapy to promote endometrial regrowth |
| Turner Syndrome (45,X) | Accelerated oocyte atresia in utero; streak gonads unable to produce estrogen; absent negative feedback | Elevated FSH and LH, very low estradiol | Hormone replacement therapy for puberty induction and maintenance; growth hormone for short stature |
The Critical Role of GnRH Pulsatility
Key Concept: The frequency of GnRH pulses determines the ratio of FSH to LH secretion:
- Slow pulse frequency (every 2-4 hours): Favors FSH secretion → promotes follicular development
- Rapid pulse frequency (every 60 minutes): Favors LH secretion → seen in polycystic ovary syndrome
- Continuous GnRH exposure: Causes receptor downregulation and gonadotropin suppression → basis of GnRH agonist therapy
- Absent or markedly reduced pulsatility: Results in hypogonadotropic hypogonadism → seen in hypothalamic amenorrhea
Often Overlooked: The Energy Balance Connection
The reproductive axis is exquisitely sensitive to energy availability. Leptin, secreted by adipose tissue in proportion to fat stores, is a key permissive signal for GnRH secretion. Even modest energy deficits (as low as 10-20% below energy needs) can suppress kisspeptin neurons and reduce GnRH pulsatility, leading to menstrual dysfunction. This explains why athletes and patients with eating disorders develop amenorrhea even before significant weight loss is apparent, and why some women with “normal” body mass index but high exercise load experience menstrual irregularity.
The Progesterone Withdrawal Principle
Normal menstruation occurs when an estrogen-primed endometrium undergoes progesterone withdrawal. This physiological principle underlies the progestogen challenge test:
| Challenge Test Result | Interpretation | Implies |
|---|---|---|
| Withdrawal bleeding present | Endometrium was estrogen-primed; outflow tract is patent | Anovulation with adequate estrogen (WHO Group II) — most commonly polycystic ovary syndrome |
| No withdrawal bleeding | Either insufficient estrogen to prime endometrium, or outflow obstruction | Requires further workup: check estradiol level; if low, evaluate for hypothalamic/pituitary cause (WHO Group I) or ovarian failure (WHO Group III); if normal, evaluate for outflow tract pathology |
Long-Term Consequences of Hypoestrogenism
Why Amenorrhea Matters Beyond Fertility
Prolonged amenorrhea with hypoestrogenism has significant health implications:
- Bone health: Estrogen deficiency leads to accelerated bone loss; women with functional hypothalamic amenorrhea lose 2-3% of bone mineral density per year
- Cardiovascular risk: Loss of estrogen’s cardioprotective effects increases cardiovascular disease risk
- Urogenital atrophy: Vaginal dryness, dyspareunia, and increased urinary tract infections
- Neurocognitive effects: Estrogen supports cognitive function and mood regulation
Conversely, chronic anovulation with adequate estrogen (as in polycystic ovary syndrome) increases risk of endometrial hyperplasia and cancer due to unopposed estrogen stimulation.
3. History Taking
A comprehensive approach to eliciting the amenorrhea and menstrual irregularity history
Red Flags — Require Urgent Evaluation
- Severe headache or visual disturbances — pituitary tumor with mass effect
- Galactorrhea with headache — prolactinoma, consider MRI urgently
- Cyclic pelvic pain without menses — outflow obstruction (hematocolpos)
- Hot flashes in woman under 40 — premature ovarian insufficiency
- Rapid virilization — androgen-secreting tumor (ovarian or adrenal)
- Significant unintentional weight loss — eating disorder, malignancy, systemic disease
- Signs of Cushing syndrome — central obesity, striae, proximal weakness
- Recent postpartum hemorrhage with failure to lactate — Sheehan syndrome
Systematic History: The “PERIODS” Approach
Use the mnemonic “PERIODS” to ensure comprehensive history taking for amenorrhea:
- P — Pregnancy and Puberty: Always exclude pregnancy first; document age at menarche, thelarche, and pubarche; was puberty normal?
- E — Eating and Exercise: Current weight and recent changes; dietary habits and restrictions; exercise intensity and duration; history of eating disorders
- R — Regularity history: Previous menstrual pattern; when did cycles become irregular; any periods in the past 3-6 months?
- I — Iatrogenic and Illness: Current medications (especially psychiatric, hormonal, antihypertensives); chronic diseases; recent surgeries (especially uterine)
- O — Other hormonal symptoms: Galactorrhea, hot flashes, vaginal dryness, hirsutism, acne, hair loss, thyroid symptoms
- D — Distress and psychosocial: Life stressors; mood changes; relationship issues; sleep disturbances; impact on quality of life and fertility goals
- S — Sexual and family history: Sexual activity and contraception; fertility attempts; family history of early menopause, polycystic ovary syndrome, thyroid disease, autoimmune conditions
The First Question
“Could you be pregnant?” — Pregnancy is the most common cause of secondary amenorrhea and must be excluded in every reproductive-aged woman before further workup, regardless of reported sexual activity or contraceptive use. A urine or serum pregnancy test should be performed early in the evaluation.
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Polycystic ovary syndrome | Irregular cycles since menarche, hirsutism, acne, weight gain, infertility | “Have your periods always been irregular, even as a teenager? Have you noticed increased facial or body hair, or worsening acne?” |
| Functional hypothalamic amenorrhea | Weight loss, excessive exercise, stress; previously regular cycles | “Have you had any recent weight changes, started a new exercise program, or been under significant stress? How many hours per week do you exercise?” |
| Hyperprolactinemia | Galactorrhea, headaches, visual changes; medication use | “Have you noticed any milky discharge from your nipples? Any headaches or changes in your vision? What medications are you taking?” |
| Premature ovarian insufficiency | Hot flashes, night sweats, vaginal dryness, mood changes; family history | “Have you experienced hot flashes, night sweats, or vaginal dryness? Did your mother or sisters go through menopause early?” |
| Thyroid dysfunction | Weight changes, fatigue, cold or heat intolerance, hair changes | “Have you noticed changes in your weight, energy level, or tolerance to temperature? Any hair loss or constipation?” |
| Asherman syndrome | History of uterine instrumentation (dilation and curettage, especially postpartum) | “Have you had any procedures on your uterus, such as a D&C after a miscarriage or delivery? Were there any complications?” |
| Outflow tract obstruction (primary amenorrhea) | Cyclic pelvic pain, normal breast development, absent menses | “Do you experience monthly cramping or pelvic pain even though you don’t have periods? Have you noticed any bulging at the vaginal opening?” |
| Constitutional delay (primary amenorrhea) | Family history of late puberty, short stature, delayed bone age | “At what age did your mother start her periods? Did any siblings develop late? How does your height compare to your family?” |
Detailed Menstrual History
For Primary Amenorrhea
- Age at thelarche: When did breast development begin? (normal: 8-13 years)
- Age at pubarche: When did pubic hair appear?
- Growth pattern: Has there been a growth spurt?
- Family history: Age of menarche in mother and sisters
- Cyclic symptoms: Any monthly pain suggesting cryptomenorrhea?
- Anosmia: Any problems with sense of smell? (Kallmann syndrome)
For Secondary Amenorrhea
- Previous pattern: What were cycles like before they stopped?
- Duration: How long since the last menstrual period?
- Onset: Was the change sudden or gradual?
- Precipitating factors: Weight change, stress, new medication, surgery?
- Associated symptoms: Hot flashes, galactorrhea, hirsutism?
- Prior fertility: Previous pregnancies and outcomes
Medication and Substance History
Medications That Cause Amenorrhea
- Antipsychotics — risperidone, haloperidol (cause hyperprolactinemia)
- Antidepressants — SSRIs, tricyclics (modest prolactin elevation)
- Antiemetics — metoclopramide, domperidone (dopamine antagonists)
- Hormonal contraceptives — progestin-only methods, post-pill amenorrhea
- GnRH agonists — leuprolide, goserelin (intentional suppression)
- Opioids — suppress GnRH pulsatility
- Chemotherapy — gonadotoxic agents cause ovarian failure
- Danazol — androgenic suppression of HPO axis
Social and Lifestyle History
- Exercise: Type, frequency, duration, intensity; competitive athletics
- Diet: Caloric restriction, food groups avoided, eating disorder behaviors
- Weight history: Current BMI, recent changes, lowest adult weight
- Stress: Major life events, chronic stressors, sleep quality
- Substance use: Cannabis (can affect HPO axis), alcohol, recreational drugs
- Occupation: Shift work, high-stress jobs, professional athletes
Relevant Family History
| Family History Item | Suggests | Why It Matters |
|---|---|---|
| Early menopause (before age 40) | Familial premature ovarian insufficiency | Some genetic causes (FMR1 premutation, BMP15) are heritable |
| Irregular periods, hirsutism, infertility | Polycystic ovary syndrome | Strong familial clustering; first-degree relatives have 40-50% risk |
| Thyroid disease | Autoimmune thyroid dysfunction | Associated with both premature ovarian insufficiency and menstrual irregularity |
| Autoimmune conditions | Autoimmune oophoritis | Type 1 diabetes, Addison disease, and others associated with ovarian failure |
| Late puberty in parents or siblings | Constitutional delay of puberty | Benign cause of primary amenorrhea; typically self-resolves |
| Intellectual disability (males) | Fragile X syndrome carrier status | FMR1 premutation causes fragile X-associated primary ovarian insufficiency |
Don’t Forget Fertility Goals
Early in the conversation, establish the patient’s reproductive goals. Ask: “Are you trying to become pregnant, or hoping to in the future?” This fundamentally shapes the urgency and direction of workup and treatment. A woman actively trying to conceive requires expedited evaluation, while someone desiring contraception needs a different approach. For patients with premature ovarian insufficiency, early discussion of fertility preservation or alternative family-building options is essential.
4. Physical Examination
A systematic approach for evaluating amenorrhea and menstrual irregularity
Systematic Framework: Use a structured “General to Specific” approach, moving from general inspection through targeted endocrine examination to pelvic assessment. The physical examination helps identify signs of underlying conditions and guides further investigation.
General Inspection
- Body habitus: Assess body mass index (BMI); note extremes (underweight or obese); body fat distribution (central versus peripheral)
- Secondary sexual characteristics: Tanner staging of breast and pubic hair development; evidence of estrogen exposure
- Signs of hyperandrogenism: Hirsutism (use Ferriman-Gallwey score), acne, male-pattern hair loss, acanthosis nigricans
- Signs of hypoestrogenism: Pale or atrophic vaginal mucosa, decreased breast fullness, fine facial wrinkles
- Cushingoid features: Moon facies, buffalo hump, central obesity with thin extremities, purple striae, easy bruising
- Turner syndrome stigmata: Short stature, webbed neck, widely spaced nipples, low hairline, cubitus valgus
Vital Signs
| Parameter | What to Assess | Clinical Significance |
|---|---|---|
| Height | Plot on growth chart for adolescents; compare to mid-parental height | Short stature suggests Turner syndrome, constitutional delay, or chronic illness |
| Weight and BMI | Calculate BMI; note recent trends if available | BMI <18.5: consider hypothalamic amenorrhea; BMI >30: associated with polycystic ovary syndrome and anovulation |
| Blood Pressure | Both arms; assess for hypertension or hypotension | Hypertension: congenital adrenal hyperplasia, Cushing syndrome; Hypotension: Addison disease, eating disorder |
| Heart Rate | Resting heart rate; assess for bradycardia or tachycardia | Bradycardia <50 bpm: severe caloric restriction, hypothyroidism; Tachycardia: hyperthyroidism, anxiety |
| Temperature | Core temperature | Hypothermia may indicate severe malnutrition or hypothyroidism |
Head and Neck Examination
Eyes
- Visual fields: Confrontation testing for bitemporal hemianopia (pituitary macroadenoma)
- Fundoscopy: Papilledema suggests increased intracranial pressure
- Exophthalmos: Graves disease (hyperthyroidism)
Thyroid
- Size: Goiter (hyper- or hypothyroidism)
- Nodules: Palpable masses require further evaluation
- Tenderness: Thyroiditis
Face
- Facial hair: Hirsutism pattern, terminal hair on upper lip, chin, cheeks
- Acne: Inflammatory acne along jawline suggests hyperandrogenism
- Moon facies: Cushing syndrome
Neck
- Webbing: Turner syndrome
- Low posterior hairline: Turner syndrome
- Lymphadenopathy: Consider systemic illness
Breast Examination
| Finding | Description | Clinical Significance |
|---|---|---|
| Tanner staging | Stage I (prepubertal) through Stage V (adult) | Breast development indicates estrogen exposure; absent development (Tanner I) in primary amenorrhea suggests gonadal dysgenesis or hypogonadism |
| Galactorrhea | Milky nipple discharge; may be spontaneous or expressible | Strongly suggests hyperprolactinemia; bilateral expression is more significant than unilateral |
| Breast atrophy | Decreased breast volume from previous baseline | Hypoestrogenic state; seen in premature ovarian insufficiency and severe hypothalamic amenorrhea |
| Widely spaced nipples | Nipples appear laterally displaced on chest wall | Turner syndrome stigmata |
Skin Examination
Signs of Hyperandrogenism
- Hirsutism: Terminal hair in male pattern (upper lip, chin, chest, abdomen, inner thighs); use Ferriman-Gallwey score (≥8 is significant)
- Acne: Inflammatory, particularly along jawline and lower face
- Androgenic alopecia: Hair thinning at crown and temporal recession
- Acanthosis nigricans: Velvety hyperpigmented plaques in axillae, neck, groin; indicates insulin resistance
Other Skin Findings
- Purple striae: Cushing syndrome (wider than normal stretch marks)
- Vitiligo: Associated autoimmune conditions; consider autoimmune premature ovarian insufficiency
- Dry skin, coarse hair: Hypothyroidism
- Lanugo: Fine downy hair; severe malnutrition/anorexia nervosa
- Easy bruising: Cushing syndrome, eating disorder
Abdominal Examination
- Body fat distribution: Central adiposity suggests insulin resistance and polycystic ovary syndrome or Cushing syndrome
- Striae: Purple-red and wide (>1 cm) suggest Cushing syndrome; white/silver striae are common and non-specific
- Pelvic mass: May indicate ovarian tumor, hematocolpos (obstructed outflow), or pregnancy
- Surgical scars: Previous pelvic surgery relevant to fertility and adhesion risk
- Adrenal masses: Rarely palpable, but consider in virilization
Pelvic Examination
External Genitalia
- Tanner staging: Pubic hair development (Stage I-V)
- Clitoromegaly: Clitoral width >10 mm or length >35 mm suggests severe hyperandrogenism or androgen-secreting tumor
- Imperforate hymen: Bulging bluish membrane in primary amenorrhea with cyclic pain
- Vaginal introitus: Confirm presence; absent in Müllerian agenesis (Mayer-Rokitansky-Küster-Hauser syndrome)
- Estrogenization: Pink, moist vaginal mucosa indicates estrogen effect; pale, thin mucosa suggests hypoestrogenism
Internal Examination
| Structure | What to Assess | Abnormal Findings and Significance |
|---|---|---|
| Vagina | Length, patency, presence of septum | Shortened or absent vagina: Müllerian agenesis, androgen insensitivity syndrome; Transverse septum: outflow obstruction |
| Cervix | Presence, appearance, discharge | Absent cervix: Müllerian agenesis; Cervical stenosis: post-procedural (cone biopsy, loop excision) |
| Uterus | Size, position, mobility, tenderness | Absent or hypoplastic: Müllerian agenesis, androgen insensitivity; Enlarged: pregnancy, fibroids |
| Adnexa | Ovarian size, masses, tenderness | Enlarged ovaries: polycystic ovary syndrome (may not be palpable); Ovarian mass: tumor, endometrioma |
Pelvic Examination in Adolescents
A full internal pelvic examination may not be necessary or appropriate in all adolescents with primary amenorrhea. External genital inspection can confirm the presence of a vaginal opening. Transabdominal or transperineal ultrasound can assess for the presence of a uterus and ovaries non-invasively. Reserve speculum and bimanual examination for cases where outflow obstruction is suspected or when the patient is sexually active.
Expected Findings by Etiology
| Condition | General Appearance | Breast/Skin | Pelvic Examination |
|---|---|---|---|
| Polycystic ovary syndrome | Often overweight/obese; normal height | Hirsutism, acne, acanthosis nigricans; normal breast development | Usually normal; occasionally enlarged ovaries palpable |
| Functional hypothalamic amenorrhea | Often thin or athletic; low BMI | No hyperandrogenism; may have lanugo; breast atrophy if prolonged | Atrophic vaginal mucosa if hypoestrogenic; normal anatomy |
| Hyperprolactinemia | Usually normal habitus | Galactorrhea (30-80% of cases); may have visual field defects | Usually normal |
| Premature ovarian insufficiency | Normal height and habitus | No hyperandrogenism; may have vitiligo or other autoimmune features | Atrophic vaginal mucosa; normal anatomy; small ovaries |
| Turner syndrome (45,X) | Short stature; webbed neck; cubitus valgus | Absent breast development (Tanner I); widely spaced nipples | Prepubertal external genitalia; streak gonads (not palpable) |
| Müllerian agenesis | Normal height and habitus; 46,XX | Normal breast development; no hyperandrogenism | Absent or short vagina; absent uterus; normal ovaries (not palpable) |
| Androgen insensitivity syndrome | Normal female phenotype; often tall; 46,XY | Normal breast development; absent or sparse pubic/axillary hair | Short blind-ending vagina; absent uterus and cervix |
| Imperforate hymen | Normal secondary sexual development | Normal breasts; no hyperandrogenism | Bulging, bluish imperforate membrane at introitus |
| Cushing syndrome | Central obesity; moon facies; buffalo hump | Purple striae; hirsutism; acne; easy bruising; proximal weakness | Usually normal |
Important Teaching Point
Normal examination is common! Many causes of amenorrhea present with entirely normal physical examination findings. Women with polycystic ovary syndrome may have no visible hirsutism (especially in certain ethnicities). Functional hypothalamic amenorrhea often occurs in normal-weight women. Hyperprolactinemia may present without galactorrhea. A normal examination does not exclude significant pathology — laboratory and imaging studies are essential to establish the diagnosis.
5. Differential Diagnosis
Systematic approach organized by probability, type, and clinical features
Primary Amenorrhea
Step-by-Step Approach to Primary Amenorrhea:
- Step 1: Assess breast development — present or absent?
- Step 2: If breasts present, confirm uterus is present (ultrasound)
- Step 3: Check gonadotropins (FSH, LH) to distinguish ovarian from central causes
- Step 4: Consider karyotype if gonadal dysgenesis suspected
With Breast Development (Estrogen Present)
| Probability | Condition | Key Features | Distinguishing Findings |
|---|---|---|---|
| COMMON | Müllerian agenesis (Mayer-Rokitansky-Küster-Hauser syndrome) | 46,XX karyotype; normal secondary sexual characteristics; absent uterus and upper vagina | Normal ovaries on imaging; absent uterus; short or absent vagina on examination |
| COMMON | Imperforate hymen | Cyclic pelvic pain; bulging perineum; hematocolpos | Bluish bulging membrane visible at introitus; pelvic mass (hematocolpos) |
| COMMON | Transverse vaginal septum | Cyclic pain; hematocolpos; variable location | Blind-ending vagina on examination; hematocolpos on ultrasound |
| LESS COMMON | Androgen insensitivity syndrome (complete) | 46,XY karyotype; female phenotype; absent pubic/axillary hair; inguinal masses (testes) | Absent uterus; blind vaginal pouch; testosterone in male range |
| LESS COMMON | Constitutional delay of puberty | Family history of late puberty; delayed bone age; eventually progresses normally | Normal anatomy; delayed but present pubertal progression |
| UNCOMMON | Cervical agenesis | Present uterus but absent cervix; cyclic pain; hematometra | Uterus present on imaging with blood accumulation |
Without Breast Development (Estrogen Absent)
| Probability | Condition | Key Features | Gonadotropins |
|---|---|---|---|
| COMMON (approximately 45%) | Turner syndrome (45,X and variants) | Short stature; webbed neck; shield chest; cardiac and renal anomalies | Elevated FSH and LH (hypergonadotropic) |
| COMMON (approximately 30%) | Constitutional delay of puberty | Family history; short stature; delayed bone age; will progress spontaneously | Low-normal FSH and LH (prepubertal pattern) |
| LESS COMMON | Kallmann syndrome | Anosmia or hyposmia; may have midline defects, renal agenesis | Low FSH and LH (hypogonadotropic) |
| LESS COMMON | Other gonadal dysgenesis (46,XX or 46,XY) | Variable phenotype; streak gonads; may have Y chromosome material | Elevated FSH and LH (hypergonadotropic) |
| UNCOMMON | Hypopituitarism | May have other pituitary hormone deficiencies; history of CNS tumor, surgery, radiation | Low FSH and LH (hypogonadotropic) |
| UNCOMMON | Functional hypothalamic amenorrhea | Severe weight loss, excessive exercise, or chronic illness in adolescence | Low FSH and LH (hypogonadotropic) |
Secondary Amenorrhea and Oligomenorrhea
Step-by-Step Approach to Secondary Amenorrhea:
- Step 1: Exclude pregnancy — always the first test
- Step 2: Check prolactin and thyroid-stimulating hormone (TSH)
- Step 3: If these are normal, assess estrogen status (progestogen challenge or estradiol level)
- Step 4: Check FSH to distinguish ovarian failure from hypothalamic-pituitary dysfunction
- Step 5: If hyperandrogenic, evaluate for polycystic ovary syndrome or other androgen excess
| Probability | Condition | Approximate Frequency | Key Distinguishing Features |
|---|---|---|---|
| COMMON | Pregnancy | Always exclude first | Positive pregnancy test; may have nausea, breast tenderness |
| COMMON | Polycystic ovary syndrome | 30-40% of secondary amenorrhea | Oligomenorrhea since menarche; hyperandrogenism; polycystic ovaries on ultrasound; often obese |
| COMMON | Functional hypothalamic amenorrhea | 20-35% | Weight loss, excessive exercise, or stress; low FSH and LH; low estradiol |
| COMMON | Hyperprolactinemia | 15-20% | Galactorrhea; headaches; visual disturbance if macroadenoma; elevated prolactin |
| LESS COMMON | Premature ovarian insufficiency | 5-10% | Age <40; hot flashes; elevated FSH (>25-40 mIU/mL on two occasions); low estradiol |
| LESS COMMON | Thyroid dysfunction | 5-10% | Hypothyroid or hyperthyroid symptoms; abnormal TSH |
| LESS COMMON | Asherman syndrome (intrauterine adhesions) | 5% | History of uterine instrumentation (especially postpartum D&C); no withdrawal bleeding to progestogen challenge despite adequate estrogen |
| UNCOMMON | Sheehan syndrome | <1% | History of severe postpartum hemorrhage; failure to lactate; fatigue; hypotension |
| UNCOMMON | Pituitary adenoma (non-functioning) | <1% | Headaches; visual field defects; may have other pituitary hormone deficiencies |
| UNCOMMON | Cushing syndrome | Rare | Central obesity; purple striae; moon facies; hypertension; elevated cortisol |
| UNCOMMON | Late-onset congenital adrenal hyperplasia | 1-5% of hyperandrogenic women | Hirsutism; elevated 17-hydroxyprogesterone (>200 ng/dL baseline or >1000 ng/dL post-ACTH) |
| UNCOMMON BUT SERIOUS | Androgen-secreting tumor (ovarian or adrenal) | Rare | Rapid virilization; testosterone often >200 ng/dL; DHEA-S >700 mcg/dL suggests adrenal source |
Anatomical (Compartmental) Approach
Compartment IV: Hypothalamus/CNS
Functional hypothalamic amenorrhea
Kallmann syndrome
Hypothalamic tumors (craniopharyngioma)
Infiltrative diseases (sarcoidosis)
Post-radiation damage
Compartment III: Pituitary
Prolactinoma
Non-functioning pituitary adenoma
Sheehan syndrome
Empty sella syndrome
Lymphocytic hypophysitis
Compartment II: Ovary
Polycystic ovary syndrome
Premature ovarian insufficiency
Gonadal dysgenesis (Turner syndrome)
Ovarian tumors
Resistant ovary syndrome
Compartment I: Uterus/Outflow
Asherman syndrome
Müllerian agenesis
Imperforate hymen
Transverse vaginal septum
Cervical stenosis
Drug-Induced Amenorrhea and Oligomenorrhea
| Drug or Drug Class | Mechanism | Characteristics | Time to Resolution After Stopping |
|---|---|---|---|
| Typical antipsychotics (haloperidol, chlorpromazine) | Dopamine receptor blockade → hyperprolactinemia | Prolactin often >100 ng/mL; galactorrhea common | Days to weeks after stopping |
| Atypical antipsychotics (risperidone, paliperidone) | Dopamine receptor blockade → hyperprolactinemia | Risperidone has highest risk; olanzapine and quetiapine lower risk | 1-3 months |
| Metoclopramide, domperidone | Dopamine antagonism → hyperprolactinemia | Often used for gastroparesis or nausea; dose-dependent effect | Days to weeks |
| Depot medroxyprogesterone acetate (DMPA) | Suppresses HPO axis; endometrial atrophy | Amenorrhea in 50% by 1 year, 80% by 5 years; intentional effect | 6-18 months after last injection |
| Levonorgestrel intrauterine system | Endometrial atrophy; partial ovulation suppression | Amenorrhea in 20-50% by 1 year; oligomenorrhea common | 1-3 months after removal |
| Continuous combined oral contraceptives | Suppresses HPO axis; thin endometrium | Intentional amenorrhea with extended-cycle regimens | 1-3 months after stopping |
| GnRH agonists (leuprolide, goserelin) | Downregulates GnRH receptors → hypogonadotropic state | Used therapeutically for endometriosis, fibroids, precocious puberty | 1-3 months after stopping |
| Opioids (chronic use) | Suppresses GnRH pulsatility | Dose-dependent; common with long-term opioid therapy | Variable; may be prolonged |
| Chemotherapy (alkylating agents) | Gonadotoxic → premature ovarian insufficiency | Risk depends on age, drug, cumulative dose; may be permanent | May be permanent (ovarian failure) |
| Danazol | Androgenic; suppresses HPO axis | Used for endometriosis; causes amenorrhea in most users | 1-2 months after stopping |
| High-dose corticosteroids | Suppresses HPO axis; may cause hyperprolactinemia | Menstrual irregularity with chronic high-dose use | Weeks to months |
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| Irregular periods since menarche + hirsutism + obesity | Polycystic ovary syndrome | Check testosterone, DHEA-S, and pelvic ultrasound |
| Amenorrhea + recent weight loss or intensive exercise | Functional hypothalamic amenorrhea | Check FSH, LH, estradiol; assess energy availability |
| Amenorrhea + galactorrhea | Hyperprolactinemia (prolactinoma) | Check prolactin; if elevated, MRI pituitary |
| Amenorrhea + hot flashes in woman under 40 | Premature ovarian insufficiency | Check FSH (repeat in 4-6 weeks if elevated); anti-Müllerian hormone |
| Primary amenorrhea + breast development + absent uterus | Müllerian agenesis or androgen insensitivity syndrome | Karyotype to distinguish 46,XX from 46,XY |
| Primary amenorrhea + no breasts + short stature | Turner syndrome | Karyotype; check FSH |
| Primary amenorrhea + no breasts + anosmia | Kallmann syndrome | Check FSH, LH (will be low); MRI for olfactory bulbs |
| Amenorrhea after uterine instrumentation (D&C) | Asherman syndrome | Progestogen challenge (no withdrawal bleed); hysteroscopy |
| Amenorrhea + failure to lactate after postpartum hemorrhage | Sheehan syndrome | Check pituitary function (cortisol, TSH, prolactin, FSH, LH) |
| Rapid virilization (months) + very high testosterone | Androgen-secreting tumor | Imaging of ovaries and adrenals; testosterone >200 ng/dL suspicious |
| Cyclic pelvic pain + primary amenorrhea + normal breasts | Outflow tract obstruction (imperforate hymen, transverse septum) | Careful perineal inspection; pelvic ultrasound for hematocolpos |
| Amenorrhea on antipsychotic medication | Drug-induced hyperprolactinemia | Check prolactin; consider switching to prolactin-sparing antipsychotic |
6. Diagnostic Investigations
A stepwise, cost-effective approach guided by clinical suspicion
First-Line Investigations for All Patients
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Urine or serum β-hCG | Exclude pregnancy | Positive or negative | ALWAYS the first test; serum more sensitive for early pregnancy |
| Serum prolactin | Screen for hyperprolactinemia | Normal: <25 ng/mL; mild elevation 25-100 ng/mL; >100 ng/mL suggests prolactinoma | Draw fasting, avoid stress; repeat if mildly elevated; macroprolactin can cause false elevation |
| Thyroid-stimulating hormone (TSH) | Screen for thyroid dysfunction | Normal: 0.4-4.0 mIU/L (varies by lab); elevated in hypothyroidism | Both hypo- and hyperthyroidism can cause menstrual dysfunction |
| Follicle-stimulating hormone (FSH) | Distinguish ovarian failure from central cause | Elevated (>25-40 mIU/mL): ovarian insufficiency; Low/normal: hypothalamic-pituitary cause | Draw on day 2-5 if any menstrual bleeding present; repeat elevated FSH in 4-6 weeks |
| Estradiol | Assess estrogen status | Low (<30 pg/mL): hypoestrogenic; Normal follicular: 30-150 pg/mL | Helps interpret FSH; low estradiol with low FSH = central cause |
| Luteinizing hormone (LH) | Assess HPO axis; evaluate LH:FSH ratio | LH:FSH ratio >2-3:1 suggests polycystic ovary syndrome (but not diagnostic) | Less useful in isolation; helps characterize HPO axis function |
Initial Workup Summary
For secondary amenorrhea, the minimum initial workup consists of:
- Pregnancy test (β-hCG)
- Prolactin
- TSH
- FSH (with or without estradiol and LH)
This combination will identify or point toward the diagnosis in approximately 85% of cases.
Targeted Investigations by Suspected Etiology
If Suspecting Polycystic Ovary Syndrome
First-Line Tests
- Total testosterone: Often elevated but may be normal; >70-80 ng/dL supports diagnosis
- Free testosterone or free androgen index: More sensitive for hyperandrogenism
- DHEA-S (dehydroepiandrosterone sulfate): Elevated suggests adrenal contribution; markedly elevated (>700 mcg/dL) suggests adrenal tumor
- Pelvic ultrasound: Polycystic ovarian morphology (≥20 follicles per ovary or ovarian volume >10 mL)
Additional Tests
- 17-hydroxyprogesterone: To exclude late-onset congenital adrenal hyperplasia (baseline >200 ng/dL requires ACTH stimulation test)
- Fasting glucose and insulin: Assess for insulin resistance
- Hemoglobin A1c: Screen for diabetes/prediabetes
- Lipid profile: Metabolic syndrome screening
- Sex hormone-binding globulin (SHBG): Low levels indicate insulin resistance and increase free androgens
If Suspecting Premature Ovarian Insufficiency
Confirmatory Tests
- FSH: Must be elevated (>25-40 mIU/mL) on TWO occasions at least 4 weeks apart
- Estradiol: Low (<30-50 pg/mL)
- Anti-Müllerian hormone (AMH): Very low or undetectable (<0.5 ng/mL); reflects remaining follicle pool
Etiological Tests
- Karyotype: Mandatory if age <30; identifies Turner syndrome mosaicism, Y chromosome material
- FMR1 premutation testing: Fragile X carrier screening; present in 3-15% of premature ovarian insufficiency
- Adrenal antibodies (21-hydroxylase antibodies): If autoimmune cause suspected
- Thyroid peroxidase (TPO) antibodies: Associated autoimmune thyroiditis
- Morning cortisol or ACTH stimulation test: If adrenal antibodies positive (Addison disease risk)
If Suspecting Hyperprolactinemia
Confirm and Characterize
- Repeat prolactin: Confirm elevation; ensure fasting, non-stressed sample
- Macroprolactin: Request if mild elevation; macroprolactin is biologically inactive
- Review medications: Drug-induced hyperprolactinemia is common
Imaging
- MRI pituitary with gadolinium: Gold standard for pituitary adenoma detection
- Indicated if: Prolactin >100 ng/mL (suggests prolactinoma); unexplained hyperprolactinemia; headaches or visual symptoms
- Note: Prolactin level roughly correlates with tumor size (microprolactinoma <1 cm usually <200 ng/mL)
If Suspecting Hypothalamic Amenorrhea
Characteristic Hormonal Pattern
- FSH and LH: Low or low-normal (often LH < FSH)
- Estradiol: Low (<30-50 pg/mL)
- Prolactin: Normal
- TSH: Normal (may have low T3 with normal TSH in energy deficiency)
Additional Assessments
- MRI pituitary: May be considered to exclude structural lesion if no clear functional cause
- DEXA scan: Bone mineral density assessment if amenorrhea >6 months
- Nutritional assessment: Resting metabolic rate, body composition
- Cortisol: May be elevated with chronic stress
If Suspecting Uterine or Outflow Tract Pathology
Imaging
- Pelvic ultrasound: First-line imaging; confirms uterine presence; identifies hematocolpos or hematometra
- Pelvic MRI: Gold standard for Müllerian anomalies; better anatomical detail than ultrasound
- Saline infusion sonohysterography: Evaluates uterine cavity for adhesions
Direct Visualization
- Hysteroscopy: Diagnostic and therapeutic for Asherman syndrome; visualizes intrauterine adhesions directly
- Examination under anesthesia: May be needed in adolescents with suspected outflow obstruction
For Primary Amenorrhea
| Clinical Scenario | Key Investigations | Expected Findings |
|---|---|---|
| Breasts present, uterus present | FSH, LH, estradiol, prolactin, TSH; pelvic ultrasound | Evaluate like secondary amenorrhea; consider outflow obstruction if hormones normal |
| Breasts present, uterus absent | Karyotype; testosterone | 46,XX → Müllerian agenesis; 46,XY with female testosterone → Complete androgen insensitivity syndrome |
| Breasts absent, uterus present | FSH, LH; karyotype | High FSH → Gonadal dysgenesis (get karyotype); Low FSH → Hypothalamic/pituitary cause (consider MRI) |
| Breasts absent, uterus absent | Karyotype; testosterone; FSH, LH | Rare; 46,XY with high testosterone → 17α-hydroxylase deficiency or agonadism |
The Progestogen Challenge Test
Using Progestogen Challenge as a Diagnostic Tool
The progestogen challenge test assesses whether the endometrium has been primed by estrogen and whether the outflow tract is patent.
Method: Give medroxyprogesterone acetate 10 mg daily for 10 days, OR micronized progesterone 200-400 mg at bedtime for 10 days.
Withdrawal Bleeding Occurs
- Indicates adequate estrogen and patent outflow tract
- Suggests anovulation with estrogen present
- Most likely diagnosis: polycystic ovary syndrome
No Withdrawal Bleeding
- Either insufficient estrogen OR outflow obstruction
- Check estradiol level to distinguish
- If estrogen low → hypothalamic-pituitary or ovarian failure
- If estrogen adequate → consider Asherman syndrome
Note: The progestogen challenge has limitations; some women with low estrogen may still bleed, and some anovulatory women may not. It is most useful in conjunction with hormone levels.
Special Investigations
| Investigation | When to Order | What It Shows | Key Values |
|---|---|---|---|
| Karyotype | Primary amenorrhea; premature ovarian insufficiency age <30; suspected gonadal dysgenesis | Chromosomal abnormalities (45,X; 46,XY; mosaicism) | Turner syndrome: 45,X or mosaic; identify Y material (gonadectomy needed) |
| Anti-Müllerian hormone (AMH) | Suspected diminished ovarian reserve; premature ovarian insufficiency | Ovarian reserve; remaining follicle pool | Very low (<0.5 ng/mL) suggests premature ovarian insufficiency; high (>4.7 ng/mL) may suggest polycystic ovary syndrome |
| FMR1 gene testing | Premature ovarian insufficiency; family history of fragile X or intellectual disability | Fragile X premutation carrier status | 55-200 CGG repeats = premutation; increased risk of premature ovarian insufficiency |
| ACTH stimulation test | Suspected late-onset congenital adrenal hyperplasia | 17-hydroxyprogesterone response to cosyntropin | Stimulated 17-OHP >1000 ng/dL confirms non-classic congenital adrenal hyperplasia |
| 24-hour urinary free cortisol or dexamethasone suppression test | Suspected Cushing syndrome | Cortisol excess | Elevated UFC (>3× upper limit) or failure to suppress cortisol after dexamethasone |
| GnRH stimulation test | Distinguish hypothalamic from pituitary cause; rarely needed | Pituitary response to GnRH | Blunted response suggests pituitary disease; may be normal in hypothalamic dysfunction |
| DEXA scan (bone mineral density) | Prolonged amenorrhea (>6-12 months); hypoestrogenic state | Bone health; osteopenia or osteoporosis | Z-score <-2.0 significant in premenopausal women |
Imaging Modalities
| Modality | Indications | Advantages | Limitations |
|---|---|---|---|
| Transvaginal ultrasound | First-line pelvic imaging; assess uterus, ovaries, follicles | Non-invasive; no radiation; real-time; assesses ovarian morphology | Operator-dependent; limited in virginal adolescents (use transabdominal) |
| Pelvic MRI | Müllerian anomalies; complex anatomy; suspected malignancy | Excellent soft tissue detail; gold standard for Müllerian anomalies | Expensive; less available; requires patient to lie still |
| MRI pituitary with gadolinium | Elevated prolactin; visual symptoms; suspected pituitary tumor | Detects microadenomas >3 mm; assesses optic chiasm | May miss very small microadenomas |
| Saline infusion sonohysterography | Suspected intrauterine pathology (adhesions, polyps) | Better uterine cavity visualization than standard ultrasound | Requires patent cervix; may be uncomfortable |
| Hysterosalpingography | Infertility workup; tubal patency; uterine cavity assessment | Assesses tubal patency; some therapeutic effect on tubes | Radiation exposure; contrast allergy risk; painful |
Cost-Effective Approach
Rather than ordering all tests at once, use a stepwise approach:
- Step 1: Pregnancy test, prolactin, TSH, FSH — identifies most common causes
- Step 2: If FSH elevated → repeat in 4-6 weeks; if confirmed → karyotype (age <30), FMR1, AMH
- Step 3: If FSH normal and hyperandrogenic → testosterone, DHEA-S, pelvic ultrasound
- Step 4: If prolactin elevated → MRI pituitary
- Step 5: If all normal with no withdrawal bleed → consider imaging for Asherman syndrome or anatomical cause
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways for amenorrhea evaluation
Step 1: Is This Urgent?
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Severe headache with visual field defects | EMERGENT | Urgent MRI pituitary; ophthalmology consultation; possible pituitary apoplexy |
| Rapid virilization (weeks to months) | EMERGENT | Check testosterone and DHEA-S immediately; urgent imaging for androgen-secreting tumor |
| Primary amenorrhea with cyclic severe pelvic pain | EMERGENT | Urgent pelvic ultrasound; likely outflow obstruction with hematocolpos requiring surgical drainage |
| Positive pregnancy test with amenorrhea | URGENT | Confirm intrauterine pregnancy; rule out ectopic pregnancy if symptomatic |
| Amenorrhea with severe malnutrition (BMI <16) or bradycardia | URGENT | Medical stabilization; assess for eating disorder; cardiology evaluation if bradycardic |
| Prolactin >200 ng/mL | URGENT | MRI pituitary within days; likely macroprolactinoma requiring treatment |
| Amenorrhea with signs of adrenal insufficiency | URGENT | Morning cortisol; if low, ACTH stimulation test; may need stress-dose steroids |
| Secondary amenorrhea without red flags | ROUTINE | Systematic workup over 2-4 weeks; pregnancy test, prolactin, TSH, FSH |
| Primary amenorrhea at age 15 with breast development | ROUTINE | Pelvic ultrasound to confirm uterine presence; hormonal evaluation |
| Oligomenorrhea with features of polycystic ovary syndrome | ROUTINE | Standard polycystic ovary syndrome workup; metabolic screening; address symptoms |
Step 2: Classify by Type
Primary Amenorrhea
Definition: No menarche by age 15 (with breasts) or age 13 (without breasts)
Key Question: Are breasts present?
Proceed to Algorithm A
Secondary Amenorrhea
Definition: Absence of menses ≥3 months (regular) or ≥6 months (irregular)
Key Question: What do initial labs show?
Proceed to Algorithm B
Step 3: Follow the Appropriate Algorithm
Algorithm A: Primary Amenorrhea
| Clinical Scenario | Most Likely Diagnosis | Next Steps |
|---|---|---|
| Breasts present + Uterus present + Normal hormones | Outflow obstruction (imperforate hymen, transverse septum) OR constitutional delay | Detailed pelvic examination; if cyclic pain, examine for imperforate hymen; if no obstruction, evaluate like secondary amenorrhea |
| Breasts present + Uterus absent + 46,XX | Müllerian agenesis (Mayer-Rokitansky-Küster-Hauser syndrome) | MRI pelvis to confirm anatomy; renal ultrasound (40% have renal anomalies); psychological support; discuss treatment options |
| Breasts present + Uterus absent + 46,XY | Complete androgen insensitivity syndrome | Testosterone (will be male range); locate gonads (may be inguinal); plan gonadectomy after puberty (malignancy risk); hormone replacement therapy |
| Breasts absent + Uterus present + High FSH | Gonadal dysgenesis (Turner syndrome most common) | Karyotype; if 45,X or mosaic → cardiac echo, renal ultrasound; hormone replacement therapy for puberty induction |
| Breasts absent + Uterus present + Low FSH | Hypothalamic or pituitary failure | MRI brain/pituitary; test smell (Kallmann syndrome); evaluate other pituitary hormones; treat underlying cause |
| Breasts absent + Uterus present + Low FSH + Anosmia | Kallmann syndrome | MRI for olfactory bulb hypoplasia; genetic testing if desired; hormone replacement therapy or pulsatile GnRH for fertility |
Algorithm B: Secondary Amenorrhea
| Lab Pattern | Most Likely Diagnosis | Next Steps |
|---|---|---|
| Positive pregnancy test | Pregnancy | Confirm intrauterine pregnancy with ultrasound; prenatal care |
| Elevated prolactin (>25 ng/mL) | Hyperprolactinemia | Review medications; repeat prolactin if mildly elevated; MRI pituitary if confirmed or >100 ng/mL |
| Abnormal TSH | Thyroid dysfunction | If TSH elevated → check free T4, treat hypothyroidism; If TSH suppressed → evaluate for hyperthyroidism |
| FSH >25-40 mIU/mL (confirmed on repeat) | Premature ovarian insufficiency | Repeat FSH in 4-6 weeks to confirm; karyotype if age <30; FMR1 testing; autoimmune screen; hormone replacement therapy |
| Normal/low FSH + Low estradiol + No hyperandrogenism | Functional hypothalamic amenorrhea | Assess weight, exercise, stress; nutritional counseling; consider MRI if no clear cause; hormone replacement therapy for bone protection |
| Normal FSH + Normal/elevated estradiol + Hyperandrogenism | Polycystic ovary syndrome | Confirm Rotterdam criteria (2 of 3: oligo/anovulation, hyperandrogenism, polycystic ovaries); metabolic workup; treat based on goals |
| Normal hormones + No withdrawal bleed + History of uterine procedure | Asherman syndrome | Saline infusion sonohysterography or hysteroscopy; hysteroscopic adhesiolysis if confirmed |
| Very high testosterone (>200 ng/dL) or DHEA-S (>700 mcg/dL) | Androgen-secreting tumor | Urgent imaging: pelvic ultrasound/MRI (ovarian) and CT adrenal; surgical referral |
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Patient wants to conceive and has polycystic ovary syndrome | Optimize weight (5-10% loss if overweight can restore ovulation); metformin if insulin resistant | Ovulation induction with letrozole (first-line) or clomiphene citrate; refer to reproductive endocrinology if fails |
| Patient wants to conceive and has premature ovarian insufficiency | Counsel about low spontaneous pregnancy rates (5-10%); discuss options | Refer to reproductive endocrinology for donor oocyte IVF; discuss adoption |
| Patient wants contraception and has polycystic ovary syndrome | Combined hormonal contraceptive (also treats hyperandrogenism) | Add spironolactone if hirsutism persists; address metabolic syndrome |
| Adolescent with functional hypothalamic amenorrhea from athletics | Multidisciplinary approach: nutritionist, sports medicine, mental health | Increase energy availability; consider transdermal estrogen with cyclic progestogen for bone protection |
| Prolactinoma identified on MRI | Start dopamine agonist (cabergoline preferred over bromocriptine) | Repeat prolactin in 4-6 weeks; repeat MRI in 3-6 months; most shrink with medical therapy |
| Turner syndrome newly diagnosed | Cardiac echo (bicuspid aortic valve, coarctation); renal ultrasound; hearing test | Hormone replacement therapy for puberty; growth hormone if short stature; lifelong cardiac surveillance |
| Y chromosome material found on karyotype | Counsel about gonadoblastoma risk (15-30% lifetime) | Refer for prophylactic gonadectomy; timing depends on clinical scenario |
| Amenorrhea persists after stopping depot medroxyprogesterone acetate | Reassure that delayed return of menses is common (median 10 months) | If no menses by 12-18 months post-last injection, evaluate as secondary amenorrhea |
| Post-pill amenorrhea beyond 3 months | This is NOT a recognized clinical entity; evaluate as secondary amenorrhea | Standard workup: pregnancy test, prolactin, TSH, FSH; do not attribute to “post-pill” effect |
| Patient declines hormone replacement therapy for premature ovarian insufficiency | Counsel strongly about bone and cardiovascular risks of untreated hypoestrogenism | Ensure adequate calcium and vitamin D; lifestyle measures; annual bone density; reassess decision periodically |
Treatment Approach Based on Patient Goals
Always Ask About Reproductive Goals First:
- Seeking pregnancy now: Expedite workup; focus on ovulation induction; refer early if needed
- Seeking pregnancy in future: Treat underlying condition; protect fertility where possible; consider fertility preservation in premature ovarian insufficiency
- Not seeking pregnancy: Focus on symptom management, bone protection, endometrial protection, and treating hyperandrogenism if present
- Seeking contraception: Combined hormonal contraceptives address multiple goals in polycystic ovary syndrome; ensure adequate progestogen for endometrial protection in anovulation
Troubleshooting: When Initial Workup Is Inconclusive
Ask These Questions
- Was pregnancy definitively excluded? Repeat β-hCG if any doubt
- Were labs drawn at the right time? FSH should ideally be early follicular phase if any bleeding
- Was prolactin sample non-stressed? Repeat fasting if borderline elevated
- Is this drug-induced? Review all medications, including over-the-counter and supplements
- Could there be multiple causes? Polycystic ovary syndrome plus hypothyroidism is not uncommon
- Is the diagnosis correct? Consider MRI pituitary if unexplained hypogonadotropic hypogonadism
- Was the progestogen challenge interpreted correctly? Light spotting counts as withdrawal bleeding
- Could this be early or impending premature ovarian insufficiency? AMH may be low before FSH rises
When to Refer to a Specialist
| Refer To | When |
|---|---|
| Reproductive Endocrinology and Infertility | Infertility with anovulation not responding to first-line treatment; premature ovarian insufficiency desiring pregnancy; complex cases |
| Endocrinology | Pituitary adenoma; Cushing syndrome; complex thyroid disease; congenital adrenal hyperplasia management |
| Gynecologic Surgery | Müllerian anomalies requiring surgery; Asherman syndrome for hysteroscopic treatment; outflow obstruction |
| Genetics | Turner syndrome or other chromosomal abnormality; FMR1 premutation carrier (family planning implications) |
| Adolescent Medicine or Eating Disorders Specialist | Suspected eating disorder; severe hypothalamic amenorrhea from energy deficit |
| Neurosurgery | Pituitary macroadenoma with mass effect not responding to medical therapy; other CNS tumors |
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
Pregnancy first, always: No matter how unlikely pregnancy seems based on history, always perform a pregnancy test before any other workup for amenorrhea. Patients may not disclose sexual activity, and contraceptive failures occur.
The “Big Five” cover 90%: Pregnancy, polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and premature ovarian insufficiency account for the vast majority of secondary amenorrhea cases. A focused initial workup will identify most diagnoses.
FSH tells you the level of the problem: High FSH indicates the ovary has failed (primary hypogonadism). Low or normal FSH with low estradiol indicates hypothalamic-pituitary dysfunction (secondary hypogonadism). This distinction guides all further workup.
Polycystic ovary syndrome is a diagnosis of exclusion: Before diagnosing polycystic ovary syndrome, exclude thyroid dysfunction, hyperprolactinemia, and non-classic congenital adrenal hyperplasia. The Rotterdam criteria require excluding other etiologies.
Prolactin level correlates with adenoma size: Microprolactinomas (<10 mm) typically cause prolactin levels of 50-200 ng/mL. Prolactin >200 ng/mL usually indicates a macroprolactinoma. Very high prolactin (>250 ng/mL) with only modest pituitary enlargement suggests “stalk effect” from a non-functioning adenoma.
Premature ovarian insufficiency requires two elevated FSH levels: Do not diagnose premature ovarian insufficiency on a single FSH. FSH can fluctuate. Confirm with a repeat measurement 4-6 weeks later before delivering this life-changing diagnosis.
Functional hypothalamic amenorrhea can occur at any weight: While often associated with low body weight, hypothalamic amenorrhea can occur in normal-weight women with energy deficit from excessive exercise or psychological stress. Focus on energy availability, not just BMI.
Breast development means estrogen exposure: In primary amenorrhea, the presence of breasts (Tanner stage 2 or higher) indicates that estrogen has been produced at some point. This immediately narrows the differential and points toward outflow obstruction or Müllerian anomalies rather than gonadal dysgenesis.
Critical Pitfalls to Avoid
Attributing amenorrhea to “post-pill” effect: “Post-pill amenorrhea” is not a recognized diagnosis. Amenorrhea persisting more than 3 months after stopping oral contraceptives requires full evaluation. The pill may have been masking underlying pathology like polycystic ovary syndrome or early ovarian insufficiency.
Missing drug-induced hyperprolactinemia: Always review the medication list before ordering an MRI for elevated prolactin. Antipsychotics, metoclopramide, and other dopamine antagonists are common causes. The prolactin level with drug-induced elevation is usually <100 ng/mL.
Forgetting the karyotype in young women with elevated FSH: In women under 30 with premature ovarian insufficiency, karyotype is mandatory. Turner syndrome mosaicism may have been missed earlier, and identifying Y chromosome material is critical because of the risk of gonadoblastoma requiring gonadectomy.
Ignoring the long-term consequences of hypoestrogenism: Young women with amenorrhea and low estrogen are losing bone mass. Hypothalamic amenorrhea, premature ovarian insufficiency, and other hypoestrogenic states require hormone replacement therapy or other bone-protective strategies, not just reassurance.
Failing to protect the endometrium in anovulation: Women with polycystic ovary syndrome and chronic anovulation are exposed to unopposed estrogen, increasing endometrial cancer risk. Ensure regular progestogen withdrawal (cyclic progestogen or combined hormonal contraceptive) to prevent endometrial hyperplasia.
Dismissing primary amenorrhea as “late bloomer”: While constitutional delay exists, primary amenorrhea warrants investigation. Turner syndrome, Müllerian agenesis, and other conditions require diagnosis for appropriate management and counseling. Do not simply wait and reassure without evaluation.
Missing rapid virilization as an emergency: Gradual hirsutism over years suggests polycystic ovary syndrome or idiopathic hirsutism. Rapid virilization (voice deepening, clitoromegaly, temporal balding over weeks to months) suggests an androgen-secreting tumor requiring urgent imaging.
Not asking about smell in primary amenorrhea with low gonadotropins: Kallmann syndrome (hypogonadotropic hypogonadism with anosmia) is easily missed if you do not specifically ask about sense of smell. Patients often do not volunteer this information as they may not realize their olfaction is abnormal.
Key Takeaways
- Always exclude pregnancy first — it is the most common cause of secondary amenorrhea and must be ruled out before further workup regardless of sexual history
- Use the compartmental approach: Hypothalamus → Pituitary → Ovary → Uterus/Outflow tract to systematically localize the cause
- FSH is your most valuable test for classification: elevated FSH indicates ovarian failure; low FSH with low estrogen indicates central (hypothalamic-pituitary) dysfunction
- The initial workup (pregnancy test, prolactin, TSH, FSH) will identify or point toward the diagnosis in approximately 85% of cases
- Polycystic ovary syndrome is the most common cause of oligomenorrhea and anovulatory secondary amenorrhea, but it is a diagnosis of exclusion — rule out other causes first
- Premature ovarian insufficiency requires two elevated FSH measurements at least 4 weeks apart; in women under 30, always obtain a karyotype
- In primary amenorrhea, the presence or absence of breast development is the key initial branch point — breasts indicate estrogen exposure and narrow the differential considerably
- Functional hypothalamic amenorrhea is a diagnosis of exclusion in women with low FSH, low estrogen, and identifiable stressors (weight loss, excessive exercise, psychological stress)
- Always consider drug-induced causes, especially medications that elevate prolactin (antipsychotics, antiemetics) and hormonal contraceptives
- Hypoestrogenic amenorrhea has long-term health consequences (bone loss, cardiovascular risk) — these patients need treatment for bone protection, not just reassurance
- Chronic anovulation with adequate estrogen (as in polycystic ovary syndrome) increases endometrial cancer risk — ensure regular progestogen exposure for endometrial protection
- Treatment approach depends on patient goals: different strategies for those seeking pregnancy now, in the future, or seeking contraception
Quick Reference Algorithm
Systematic Approach to Amenorrhea:
- Exclude pregnancy — Urine or serum β-hCG in all reproductive-aged women
- Obtain initial labs — Prolactin, TSH, FSH (± estradiol, LH)
- Interpret FSH level:
- High FSH → Ovarian failure (premature ovarian insufficiency, gonadal dysgenesis) → Repeat to confirm, then karyotype if age <30, FMR1 testing
- Low/normal FSH with low estradiol → Central cause (hypothalamic or pituitary) → Assess for weight loss, exercise, stress; consider MRI pituitary
- Normal FSH with normal estradiol → Anovulation with estrogen present → Consider polycystic ovary syndrome; check androgens
- If prolactin elevated → Rule out medications; if unexplained or >100 ng/mL → MRI pituitary
- If TSH abnormal → Treat thyroid dysfunction; menses often normalize
- If hyperandrogenism present → Evaluate for polycystic ovary syndrome (Rotterdam criteria), late-onset congenital adrenal hyperplasia (17-hydroxyprogesterone), or tumor (if rapid virilization)
- If all tests normal and no withdrawal bleed → Evaluate for outflow obstruction or Asherman syndrome (hysteroscopy, saline infusion sonohysterography)
- For primary amenorrhea — First determine if breasts are present (estrogen exposure), then confirm uterine presence with imaging before hormonal workup
- Tailor treatment to patient’s reproductive goals, underlying diagnosis, and need for bone/endometrial protection
- Refer to specialist when diagnosis uncertain, infertility treatment needed, surgical intervention required, or complex multidisciplinary care indicated